Insight Molecular Diagnostics Inc. (IMDX) is a Healthcare · Diagnostics & Research company listed on NASDAQ. Price $3.87 (-2.03%), Market cap $0.19B, 52-week low–high $2.40 ~ $8.48.
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers GraftAssureCore test, a blood test designed to measure dd-cfDNA using a novel PCR-based measurement platform, for potential patient registrants; GraftAssureIQ, a transplant monitoring a
Financial statements, price targets, institutional (13F) holdings and related news for Insight Molecular Diagnostics Inc. are updated in real time on BlackAll Trade.
Insight Molecular Diagnostics Inc. trades at $3.87 (-2.03%). Real-time quotes and charts are available on BlackAll Trade.
Insight Molecular Diagnostics Inc. has a market cap of about $0.19B.
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted rese